HOME > COLUMN
COLUMN
- Eliminating Bias from the Interview Process
January 23, 2015
- Loss Aversion: Why Candidates Reject Offers
December 26, 2014
- What You Don’t Know About Communication Can Hurt You
November 28, 2014
- 3 Reasons Why KOL Management Is No Longer Enough
October 22, 2014
- Successful People Have the Best Information
September 24, 2014
- Is Your Body Language Louder than Your Speech?
August 25, 2014
- Taking Pride in Small Things Makes Big Things Possible
July 25, 2014
- It’s Moments Like These
June 27, 2014
- How to Hire a Medical Doctor Who Is a Business Person First
May 23, 2014
- Transforming from a Key Opinion Leader to a Key Account
April 25, 2014
- Emerging Immunotherapy of Cancer: 2
April 11, 2014
- Emerging Immunotherapy of Cancer: 1
April 10, 2014
- Sun Tzu and the Art of Interviewing
March 18, 2014
- 2014: Year of the (Trojan) Horse – CROs Are about to Take the Pharma Industry by Storm
February 21, 2014
- The Time Is Now for Medical Affairs
January 17, 2014
- Blue Ocean Recruiting
December 20, 2013
- Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
- Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
- A World of Opportunity for the Brave
November 1, 2013
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…